BTIG sets a USD 70 target for Pulse Biosciences stock
Published on 10/05/2026 at 09:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Pulse Biosciences (ISIN US74587B1017) was trading at EUR 42.70 at Lang & Schwarz on October 5, 2026 at 9:40 a.m. CEST, up 0.71 percent versus the prior close of EUR 42.40. The latest analyst event came on September 23, 2026, when BTIG initiated coverage with a Buy rating and a USD 70.00 price target, as MarketBeat reported.
BTIG highlights the clinical platform
The BTIG target followed a series of clinical milestones around Pulse Biosciences' nanosecond pulsed field ablation technology. The rating source cited early clinical evidence and the company's development programs, while the September 23, 2026 report placed the target above the broader consensus target of USD 50.20, also reported by MarketBeat.
Clinical execution supplied the most recent operating milestone. Pulse Biosciences said on September 15, 2026, that it had enrolled the 100th patient in the PRECISE-BTN study, doubling the original 50-patient design across three U.S. clinical sites, according to Business Wire.
Revenue remains early stage
The latest reported quarter ended June 30, 2026. Pulse Biosciences posted revenue of USD 434,000 and earnings per share of minus USD 0.36, missing the consensus estimate of minus USD 0.29, while revenue was below the USD 0.53 million estimate, according to MarketBeat. The comparison shows the central tension in the story: clinical progress is advancing faster than commercial revenue.
Pulse Biosciences describes its CellFX System and Nano-Pulse Stimulation technology as bioelectric medicine platforms designed to affect targeted cells while limiting thermal damage to surrounding tissue, according to the company's investor-relations page at Pulse Biosciences. The next report date is November 16, 2026, with the reporting period identified as the third quarter of 2026 by TradingView.
PLSE trades below its yearly high
At Lang & Schwarz, Pulse Biosciences was trading intraday at EUR 42.70 on October 5, 2026 at 9:40 a.m. CEST, plus 0.71 percent versus the Lang & Schwarz prior close of EUR 42.40 on October 2, 2026. The primary listing is on Nasdaq in USD, while the reference price for this article is the euro quotation from Lang & Schwarz.
Pulse Biosciences at a glance
- Company: Pulse Biosciences, Inc.
- ISIN: US74587B1017
- Ticker: PLSE
- Primary exchange: NASDAQ
- Price Lang & Schwarz as of October 5, 2026, 9:40 a.m. CEST: EUR 42.70
- Change versus prior close: plus 0.71 percent
- Prior close Lang & Schwarz October 2, 2026: EUR 42.40
- Market capitalization: USD 3.3 billion as of October 2, 2026
- Sector / Industry: Healthcare / Medical Instruments and Supplies
- Next earnings date: November 16, 2026
